Cannabis May Help Cancer Patients Tolerate Immunotherapy — But Could Reduce Its Effectiveness
Cannabinoids appear to reduce immune-related side effects of checkpoint inhibitor immunotherapy, but their immunosuppressive action through CB2 receptors may simultaneously undermine the anti-cancer immune response these drugs are designed to boost.
Quick Facts
What This Study Found
Cannabis use in cancer patients receiving immune checkpoint inhibitors (ICIs) reduces immune-related adverse events and improves tolerability, but several studies noted potential negative effects on clinical outcomes including overall survival and progression-free survival, possibly due to CB2-mediated immunosuppression.
Key Numbers
The review proposes that CB2 functions as an inhibitory immune checkpoint. CBD and CBG, with minimal CB2 agonism, may be safer therapeutic choices than THC during immunotherapy. MAGL inhibitors are also suggested as a complementary strategy.
How They Did This
Narrative review examining clinical studies of concurrent cannabinoid and immune checkpoint inhibitor use in cancer patients, alongside mechanistic analysis of CB2 receptor immunosuppressive signaling and its potential to function as an inhibitory immune checkpoint.
Why This Research Matters
Immune checkpoint inhibitors are among the most important cancer treatments developed in decades, but their side effects limit use. If cannabinoids can manage these side effects without undermining treatment efficacy, they could help more patients complete their immunotherapy courses.
The Bigger Picture
This review reframes the CB2 receptor as an immune checkpoint — a provocative idea that could change how oncologists think about cannabis use during immunotherapy. The recommendation to favor CBD/CBG over THC during immunotherapy could have immediate clinical relevance.
What This Study Doesn't Tell Us
Narrative review — not a systematic review or meta-analysis. Clinical evidence is limited to a few observational studies. The CB2 immune checkpoint hypothesis, while biologically plausible, has not been directly tested in clinical trials.
Questions This Raises
- ?Would switching from THC to CBD/CBG during immunotherapy preserve symptom relief without undermining treatment?
- ?Could CB2 antagonists be co-administered with cannabinoids to block immunosuppressive effects?
- ?Should oncologists screen for cannabis use before starting ICIs?
Trust & Context
- Key Stat:
- Evidence Grade:
- Narrative review synthesizing limited clinical data with mechanistic rationale. Hypothesis-generating but not definitive.
- Study Age:
- Published 2025.
- Original Title:
- Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.
- Published In:
- Frontiers in immunology, 16, 1497829 (2025)
- Authors:
- Vigano, MariaLuisa(3), Wang, Lixing(2), As'sadiq, Alia(2), Samarani, Suzanne, Ahmad, Ali, Costiniuk, Cecilia T
- Database ID:
- RTHC-07868
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Should I stop using cannabis during immunotherapy?
This review suggests cannabis may reduce immunotherapy effectiveness through CB2 activation. Discuss with your oncologist — CBD or CBG may be safer options than THC-heavy products during treatment, but clinical evidence is still limited.
Why might CBD be better than THC during immunotherapy?
THC strongly activates CB2 receptors, which suppress immune function. CBD and CBG have minimal CB2 activity, so they may provide symptom relief without undermining the immune response that immunotherapy needs to fight cancer.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- why-does-weed-make-music-sound-better
- why-does-weed-give-cotton-mouth-salivary
Cite This Study
https://rethinkthc.com/research/RTHC-07868APA
Vigano, MariaLuisa; Wang, Lixing; As'sadiq, Alia; Samarani, Suzanne; Ahmad, Ali; Costiniuk, Cecilia T. (2025). Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.. Frontiers in immunology, 16, 1497829. https://doi.org/10.3389/fimmu.2025.1497829
MLA
Vigano, MariaLuisa, et al. "Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.." Frontiers in immunology, 2025. https://doi.org/10.3389/fimmu.2025.1497829
RethinkTHC
RethinkTHC Research Database. "Impact of cannabinoids on cancer outcomes in patients receiv..." RTHC-07868. Retrieved from https://rethinkthc.com/research/vigano-2025-impact-of-cannabinoids-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.